Minneapolis, United States
Neurotype Inc., founded in 2019 and headquartered in the United States, is at the forefront of integrating advanced technologies in healthcare, particularly for addiction treatment. The company operates in the intersecting fields of Health Care, Information Technology, and Medical Devices.
With the compelling slogan, "Brain-based solutions to disarm cravings for precision relapse prevention," Neurotype Inc. focuses on developing innovative brain sensors and digital therapeutics. Their groundbreaking work includes an FDA-regulated device employing novel neurofeedback to personalize the prevention strategy for drug craving and relapse, especially targeting Opioid Use Disorder.
Recently, the company secured a $328.96K Seed Round investment on 30 September 2023, backed by the National Institute on Drug Abuse (NIDA). This funding reflects strong confidence from a reputable source, positioning Neurotype Inc. for significant strides in addiction therapy innovations.
-logo.jpg){kind=logo}
